CMR Substudy of Coronary Sinus Reducer for Management of Symptomatic Heart Failure With Preserved Ejection Fraction Associated With Coronary Microvascular Dysfunction

What this Trial Is About

Researchers are evaluating the effect of coronary sinus (CS) reducer implantation in patients who have heart failure with preserved ejection fraction (HFpEF) combined with coronary microvascular dysfunction (CMD). The study aims to measure myocardial ischemia by using stress myocardial perfusion assessed through cardiovascular magnetic resonance (CMR). This observational research is sponsored by the Mayo Clinic and focuses on patients with these specific heart conditions. Participants diagnosed with HFpEF, non-obstructive coronary artery disease, and documented CMD will undergo a 50-minute non-invasive stress perfusion CMR test. The study involves observing changes in heart muscle blood flow by measuring the endocardial to epicardial perfusion ratio at the start and after 6 months. This diagnostic approach helps researchers understand how the CS reducer may influence heart muscle perfusion. Throughout the study, participants will be involved in CMR imaging sessions to assess heart function and blood flow under stress conditions. The primary outcome measured is the change in the endocardial to epicardial perfusion ratio between baseline and 6 months. Patients must consent to participate and be enrolled in the main CS reducer HFpEF study. The total duration includes initial imaging and follow-up after six months to monitor changes.

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD